Jazz Pharmaceuticals said Thursday that the highest dose of suvecaltamide failed a Phase 2b trial in essential tremor, a neurological condition that causes involuntary shaking …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Dive Brief: Harbinger Health has raised $140 million to clinically validate a blood-based cancer screening test ahead of a planned launch in 2025. The test
The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. Arghavan Salles, MD, PhD, polled her audience on X: why
Relapses in a common form of leukemia may be preventable following new research which has identified how the cancer develops resistance to first line treatments.